These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21046291)

  • 21. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
    Ridker PM; MacFadyen J; Cressman M; Glynn RJ
    J Am Coll Cardiol; 2010 Mar; 55(12):1266-1273. PubMed ID: 20206456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy.
    Rabkin SW; Langer A; Ur E; Calciu CD; Leiter LA
    Hypertens Res; 2013 Jun; 36(6):550-8. PubMed ID: 23388885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
    Gortney JS; Sanders RM
    Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of C-reactive protein when prescribing a statin.
    Kinlay S
    Curr Atheroscler Rep; 2012 Feb; 14(1):26-32. PubMed ID: 22125118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?
    Ferdinand KC
    Curr Atheroscler Rep; 2011 Feb; 13(1):64-72. PubMed ID: 21104458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
    Matsuo Y; Hashizume T; Shioji S; Akasaka T
    Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
    Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
    Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.
    Kostapanos MS; Elisaf MS
    World J Cardiol; 2011 Jul; 3(7):207-14. PubMed ID: 21860701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ
    Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Another look at the results of the JUPITER trial.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
    Ndumele CE; Pradhan AD; Ridker PM
    J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study.
    Yang EY; Nambi V; Tang Z; Virani SS; Boerwinkle E; Hoogeveen RC; Astor BC; Mosley TH; Coresh J; Chambless L; Ballantyne CM
    J Am Coll Cardiol; 2009 Dec; 54(25):2388-95. PubMed ID: 20082929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.